Gideon Capital Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Gideon Capital Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-17,734	Closed	-$1.92M	–	237
2019 Q4	$1.92M	Buy	17,734 +10,092	+132%	+$1.08M	0.66%	51
2019 Q3	$748K	Buy	7,642 +352	+5%	+$39.7K	0.24%	139
2019 Q2	$955K	Buy	+7,290	New	+$940K	0.33%	117
2019 Q1	–	Sell	-8,358	Closed	-$814K	–	554
2018 Q4	$814K	Buy	+8,358	New	+$988K	0.33%	89
2018 Q3	–	Sell	-2,472	Closed	-$307K	–	526
2018 Q2	$307K	Buy	+2,472	New	+$289K	0.15%	252
2017 Q4	–	Sell	-4,471	Closed	-$627K	–	439
2017 Q3	$627K	Buy	4,471 +807	+22%	+$110K	0.62%	24
2017 Q2	$446K	Buy	3,664 +1,511	+70%	+$176K	0.49%	62
2017 Q1	$261K	Buy	+2,153	New	+$278K	0.16%	297
2015 Q2	–	Sell	-1,166	Closed	-$202K	–	333
2015 Q1	$202K	Buy	+1,166	New	+$211K	0.08%	210
2014 Q3	–	Sell	-10,098	Closed	-$1.58M	–	381
2014 Q2	$1.58M	Buy	+10,098	New	+$1.59M	0.57%	58

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Gideon Capital Advisors's ALXN Position: Q1 2020 in Review

Gideon Capital Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 17,734 shares — an estimated $1.92M sold.

Gideon Capital Advisors first reported a position in ALXN in Q2 2014 and held it in 10 quarters. The position peaked at $1.92M in Q4 2019. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

Gideon Capital Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Gideon Capital Advisors sold 17,734 Alexion Pharmaceuticals shares in Q1 2020, an estimated $1.92M.
Gideon Capital Advisors first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 10 quarters.
Gideon Capital Advisors's Alexion Pharmaceuticals position peaked at $1.92M in Q4 2019.
654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Gideon Capital Advisors's 13F filing for Q1 2020.